The EvolutTM R valve was built on the proven design of our CoreValveTM system. The Evolut R valve features a supra-annular design and low delivery profile.DOWNLOAD BROCHURE
The Evolut R transcatheter aortic heart valve can be recaptured and repositioned. Its self-expanding nitinol frame enhances the ability to conform and seal to the native annulus. The supra-annular leaflet position keeps the working portion of the valve above and unconstrained by the native annulus.
The Evolut R valve is built on a proven platform, which continues to demonstrate exceptional outcomes.
Manufacturing the CoreValve Evolut R TAV
The supra-annular valve design of the nitinol frame maximizes the valve orifice and leaflet coaptation.1
The Evolut R valve design promotes single-digit gradients and large effective orifice areas (EOAs): The supra-annular valve optimizes coaptation in noncircular anatomy with supra-annular valve position and conforms to the native annulus.
Features of the EnVeoTM PRO delivery system allow you to treat more patients and position the valve more accurately.
Broadest annulus range*
More patients have access to the minimally invasive TAVR procedure because of the expanded annulus range.
Lowest delivery profile
The EnVeo PRO system retains its outer diameter as it enters the vessel and remains at this diameter as it is advanced to the annulus.
Recapture and reposition
The EnVeo PRO delivery system assists in accurate positioning of the valve. The delivery system features a 1:1 response, thus providing immediate feedback between the deployment knob and the movement of the capsule.
In addition, the EnVeo PRO delivery system provides you the option to recapture and reposition2 for more accurate placement.
The Confida™ Brecker guidewire (CBG) was specifically designed for TAVR procedures.
Access instructions for use and other technical manuals in the Medtronic Manual Library. Search by the product name (e.g., Evolut) or model number. You may also call 800-961-9055 for a copy of a manual.
Broadest annulus range based on CT derived diameters.
Measurement is for TAV-in-SAV only.
Popma JJ, Reardon MJ, Khabbaz K, et al. Early Clinical Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Who Are Suboptimal for Surgery: Results of the Evolut R U.S. Study. JACC Cardiovasc Interv. February 13, 2017;10(3):268-275.
Up to 80% deployment. The valve can be partially or fully recaptured up to three times prior to the point of no recapture. Third attempt must be a complete recapture and retrieval from patient.